What does Pasireotide do?

Pasireotide is described as a second-generation somatostatin analog and cyclic six-amino-acid peptide. The source highlights use in Cushing's disease and acromegaly, while also emphasizing that elevated blood glucose is a major limitation reported in clinical use.

How does Pasireotide work?

The source reports that Pasireotide binds SSTR1, SSTR2, SSTR3, and SSTR5, with strongest affinity for SSTR5. In Cushing's disease, SSTR5 expression on corticotroph tumors is linked to lower ACTH output; in acromegaly, SSTR2 and SSTR5 engagement is described on growth-hormone-secreting tumors. Effects on insulin and incretin hormones are presented as a proposed reason for frequent hyperglycemia.

Is Pasireotide FDA approved?

Yes. The supplied source lists Pasireotide as FDA approved for Cushing's disease and acromegaly.

What side effects are reported for Pasireotide?

Reported adverse effects include hyperglycemia or diabetes, diarrhea, nausea, gallstones, QT prolongation, liver enzyme elevations, and adrenal insufficiency. The source marks hyperglycemia/diabetes as very common and QT prolongation as serious.

What dose information is reported for Pasireotide?

The source lists a community-reported common dose of 300-900 mcg twice daily, a 300-900 mcg per-dose range, and subcutaneous or intramuscular administration. It also includes a research/FDA-labeling row of 600-900 mcg SC twice daily. These entries are evidence summaries, not dosing guidance.

Hormonal FDA Approved - approved for specific uses

Pasireotide

Also known as: Signifor, Signifor LAR

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

FDA-approved somatostatin analog peptide researched for Cushing's disease and acromegaly.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

300–900mcg

Subcutaneous or intramuscular

Researched for

Cushing's disease, acromegaly, hormone disorders

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

Pasireotide is a single- somatostatin analog also known by the aliases Signifor and Signifor LAR.
The source lists FDA-approved status for Cushing's disease and acromegaly.
Reported dosing formats include twice-daily use and a monthly LAR option, with subcutaneous or intramuscular administration noted.
Research and safety discussion in the source centers on cortisol or biochemical control outcomes alongside frequent hyperglycemia.

How it's thought to work

Pasireotide is reported to act across four somatostatin receptor subtypes: SSTR1, SSTR2, SSTR3, and SSTR5. The source emphasizes SSTR5 affinity, which is relevant to corticotroph tumors in Cushing's disease and ACTH suppression. For acromegaly, the described receptor targets include SSTR2 and SSTR5 on tumors that secrete growth hormone. The same receptor activity in pancreatic and gastrointestinal tissues is presented as a contributor to reduced insulin, , and GIP signaling, which may explain the high rate of hyperglycemia reported in trials.

What the research shows

Where the research stands

The source describes randomized clinical evidence in Cushing's disease and acromegaly. In the 12-month Cushing's disease phase 3 study, 162 participants were randomized and urinary free cortisol normalization was reported in about 15% to 26% depending on dose, along with broader cortisol reductions and symptom measures. In acromegaly, the PAOLA phase 3 trial is described as showing biochemical control in roughly 15% to 20% of patients receiving pasireotide LAR after inadequate response to octreotide or lanreotide, compared with 0% in those continuing older analog therapy. Across these trial summaries, hyperglycemia is a repeated safety concern, with glucose-lowering medication sometimes needed.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA approved for Cushing's disease and acromegaly FDA Approved

Typical dosing

CommunityCommunity dataset

300–900 mcg

twice daily

300 mcgfull range seen900 mcg

Community-reported dosing for a somatostatin analog entry in Cushing's disease; source notes a higher hyperglycemia concern than with other somatostatin analogs.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

600-900 mcg SC twice daily

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Long-term / chronic use
Administration: Subcutaneous or intramuscular

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source does not identify a universally preferred clock time; it frames timing as protocol-dependent and notes that regularity may matter more than a specific time of day.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Hyperglycemia and diabetes
Diarrhea
Nausea
Gallstones
QT prolongation
Liver enzyme elevations
Adrenal insufficiency

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

cyclo[Hyp(amec)-Phg-D-Trp-Lys-Tyr(Bzl)-Phe] (cyclic modified hexapeptide)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Pasireotide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Pasireotide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions